To include your compound in the COVID-19 Resource Center, submit it here.

Reolysin: Interim Phase II data

Interim data from 20 evaluable patients in an ongoing, single-arm, open-label, U.S. Phase

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE